(Abstracted from N Engl J Med 2022;386:437–448)
Little consensus exists on optimal treatment for advanced or recurrent endometrial cancer after disease progression with platinum-based chemotherapy. Lenvatinib is a multitargeted tyrosine kinase inhibitor that as a single agent has demonstrated limited efficacy as second-line treatment of recurrent endometrial carcinoma.
(Abstracted from N Engl J Med 2021;385:1856–1867)Platinum-based chemotherapy plus bevacizumab and paclitaxel is the standard first-line therapy for persistent, recurrent, or metastatic cervical cancer. The phase 2 KEYNOTE-158 trial found evidence of a response to pembrolizumab among patients with programmed death ligand-1 (PD-L1) positive cervical cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.